STOCK TITAN
  1. Home
  2. News
  3. AEZS

Aeterna Zentaris, Inc. - AEZS STOCK NEWS

Welcome to our dedicated page for Aeterna Zentaris news (Ticker: AEZS), a resource for investors and traders seeking the latest updates and insights on Aeterna Zentaris stock.

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZS) is a global biopharmaceutical company specializing in endocrine therapy and oncology. With a robust track record in drug discovery, development, and commercialization, the company focuses on addressing significant unmet medical needs. Aeterna Zentaris' flagship product, macimorelin (marketed as Macrilen® in the U.S. and Ghryvelin™ in Europe), is the first and only FDA and European Commission-approved oral test for diagnosing adult growth hormone deficiency (AGHD). The company is actively pursuing the extension of macimorelin’s application for diagnosing childhood-onset growth hormone deficiency (CGHD), with the Phase 3 DETECT trial nearing completion.

Recently, Aeterna Zentaris announced a definitive agreement to merge with Ceapro Inc. The merger, expected to close in the second quarter of 2024, aims to leverage Ceapro's revenue-generating cosmeceutical and nutraceutical products, such as oat beta glucan and avenanthramides. The combined entity is poised to generate stable cash flow, diversify its product pipeline, enhance research and development capabilities, and strengthen its market presence in both North America and Europe.

The company remains committed to developing an array of therapeutic assets, including treatments for neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism, and amyotrophic lateral sclerosis (ALS). Aeterna Zentaris is well-capitalized, with a strategic plan to advance innovative products and deliver sustained value to its shareholders.

News

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Rhea-AI Summary
Aeterna Zentaris Inc. and Ceapro Inc. announce the approval of their all-stock merger of equals transaction by securityholders. The voting results show strong support for the merger, with Aeterna shareholders approving the transaction by high percentages. The merger is expected to create a sustainable business for delivering value to the biopharma sector and shareholders. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

Rhea-AI Summary
Aeterna Zentaris Inc. recommends shareholders vote for the merger with Ceapro Inc. to create a diversified biopharmaceutical company. The merger aims to combine Ceapro's revenue-generating cosmeceutical business with Aeterna's pipeline of higher-margin pharmaceutical products, potentially leading to stable cash flow, diversified product pipeline, and expanded R&D capabilities. The merger is expected to provide a compelling value proposition and lower risk profile for the combined company and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

Rhea-AI Summary
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) have announced a definitive agreement to combine operations in an all-stock merger of equals transaction. The combined company is expected to be listed on the Nasdaq Capital Market and the Toronto Stock Exchange, creating a long-term sustainable business optimally positioned to deliver value as the biopharma sector recovers. Shareholders of each company will share in future value creation, with existing securityholders of Aeterna and Ceapro to each own 50% of the combined company, respectively. The transaction is expected to close in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.92%
Tags
acquisition
News

Aeterna Zentaris Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) reported the launch of Ghryvelin™ in key European countries, approval of Macrilen® in South Korea, and ended the quarter with $38.8 million in cash, projecting funding into 2025. The company's financial results for the quarter ended September 30, 2023, show a net loss of $4.1 million and a revenue decrease of $1.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

Rhea-AI Summary
Aeterna Zentaris Inc. announced that its CEO, Dr. Klaus Paulini, will participate in the Virtual Investor Ask the CEO Conference on October 25th. Investors can submit questions live or pre-submit them through the event's website. The presentation will be available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
conferences
-
News

Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Aeterna Zentaris CEO to present at H.C. Wainwright conference, focusing on AIM Biologicals development programs for NMOSD and PD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Aeterna Zentaris Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

Rhea-AI Summary
Aeterna Zentaris Inc. provides an update on its therapeutic and diagnostic development pipeline programs. The company is making progress in patient recruitment for its DETECT clinical trial and expects to complete the study by the end of the year. Aeterna also plans to secure a development and commercialization partner for Macrilen® for the U.S. and Canada. In terms of therapeutics development, the company is focused on autoimmunity modifying fusion proteins for the potential treatment of neuromyelitis optica spectrum disorder and Parkinson's disease. They have received positive feedback from their collaborator and scientific advisor on the NMOSD indication. Aeterna is also working on a potential treatment for chronic hypoparathyroidism and a ghrelin agonist for the treatment of ALS. The company has a strong financial position with cash projected to fund operations and pipeline programs into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

Rhea-AI Summary
Aeterna Zentaris Inc. announced that its CEO and Managing Director will participate in a virtual investor event on July 13th. The presentation will be available via live webcast and a replay will be accessible for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none

FAQ

What is the current stock price of Aeterna Zentaris (AEZS)?

The current stock price of Aeterna Zentaris (AEZS) is $5.43 as of August 8, 2024.

What is the market cap of Aeterna Zentaris (AEZS)?

The market cap of Aeterna Zentaris (AEZS) is approximately 17.5M.

What is Aeterna Zentaris Inc. focused on?

Aeterna Zentaris Inc. specializes in endocrine therapy and oncology, focusing on drug discovery, development, and commercialization.

What is macimorelin?

Macimorelin is an oral drug approved by the FDA and European Commission for diagnosing adult growth hormone deficiency. It is also being developed for childhood-onset growth hormone deficiency.

What recent merger has Aeterna Zentaris announced?

Aeterna Zentaris announced a merger with Ceapro Inc., expected to close in the second quarter of 2024, aimed at leveraging Ceapro's revenue-generating cosmeceutical and nutraceutical products.

What are some products offered by Ceapro?

Ceapro produces active ingredients like oat beta glucan and avenanthramides, used in leading skincare brands such as Aveeno and Jergens.

What is the significance of the DETECT trial?

The DETECT trial is a Phase 3 study evaluating macimorelin for diagnosing childhood-onset growth hormone deficiency. Completion is expected in the second quarter of 2024.

What therapeutic areas is Aeterna Zentaris developing products for?

Aeterna Zentaris is developing therapeutic assets for neuromyelitis optica spectrum disorder, Parkinson's disease, hypoparathyroidism, and amyotrophic lateral sclerosis.

What are the financial conditions of Aeterna Zentaris?

As of recent reports, Aeterna Zentaris is well-capitalized, with $34 million in cash as of December 31, 2023, expected to fund operations through 2024 and into 2025.

What strategic advantages will the merger with Ceapro bring?

The merger is expected to create stable cash flow, diversify the product pipeline, enhance research and development capabilities, and strengthen market presence in North America and Europe.

What are the anticipated benefits of the combined company post-merger?

The combined company aims to deliver value by leveraging revenue from existing products, advancing a diversified pipeline, and achieving operational synergies.

Where can I find more information about Aeterna Zentaris?

For more information, visit the company's website at www.zentaris.com and connect with them on LinkedIn and Facebook.

Stock AEZS logo
Aeterna Zentaris, Inc.

Nasdaq:AEZS

AEZS Rankings

#5359 Ranked by Market Cap
N/A Ranked by Dividends

AEZS Stock Data

17.51M
3.06M
1.32%
5.21%
0.19%
Biotechnology
Healthcare
Link
United States of America
Toronto